Abate As Indust (531658)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter shows a net profit of ₹3 crore against a small ₹14 crore market cap, indicating a potential earnings inflection.
• Reported profit growth of 1000% suggests a dramatic improvement from a depressed base.
• Piotroski F-Score of 5/9 is moderate and not entirely negative from a financial health standpoint.
• Price at ₹28.64 near the top of the 52-week range reflects renewed market interest.

Concerns

• ROE of -195.77% and ROCE of 0.00% point to severely weak or negative capital productivity.
• Book value and debt/equity are unavailable, making balance sheet risk impossible to assess.
• Sales growth is 0.00%, so the profit jump is not backed by top-line expansion and may be one-off.
• Trailing P/E of 18.03 is inconsistent with the ₹3 crore quarterly profit, raising doubt about earnings sustainability.

AI Analysis

Let me begin with the numbers that matter. Abate As Indust has a market cap of just ₹14 crore, yet it reported sales of ₹43 crore in the latest quarter and a net profit of ₹3 crore. On the surface, that seems extraordinarily cheap. But a value investor must not be seduced by one quarter. The trailing P/E of 18.03 implies earnings of only about ₹0.78 crore, so the ₹3 crore quarterly profit is not yet reflected in the annual earnings stream. Profit growth of 1000% sounds dramatic, but it often means the base was tiny or negative. Sales growth is zero, so there is no revenue engine driving this improvement; it may be a restructuring or one-off event. The financial health is a serious concern. ROE is minus 195.77% and ROCE is 0.00%. Book value is not available, and debt-to-equity is not available. When I cannot see the equity or debt clearly, and the return on equity is deeply negative, I assume the balance sheet is fragile. A business trading at ₹28.64, near its 52-week high of ₹28.64, after starting the range at ₹9.26, is being repriced. That may be market optimism, not investment evidence. What do I like? The Piotroski F-score of 5 out of 9 is mediocre, not terrible. The latest quarter is profitable, and if it sustains, the valuation would be attractive. But with no moat, no dividend, no promoter holding data, and an industry classification of hospitals, I cannot conclude this is a high-quality compounder. At best, this is a turnaround situation. The market is paying for a future that may not exist. I would need several quarters of proof, a healthy balance sheet, and honest disclosure before I would commit a rupee. Speculation is not investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer